Patents by Inventor Michael C. Sanguinetti

Michael C. Sanguinetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
    Patent number: 7247436
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: July 24, 2007
    Assignee: University of Utah Research Foundation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
  • KVLQT1—a long QT syndrome gene
    Patent number: 6972176
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: December 6, 2005
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski, Qing Wang
  • Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
    Publication number: 20040235038
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCAE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Application
    Filed: June 7, 2004
    Publication date: November 25, 2004
    Applicant: University of Utah Research Foundation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
  • KVLQT1 - a long QT syndrome gene
    Publication number: 20030170708
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Application
    Filed: February 20, 2003
    Publication date: September 11, 2003
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Diagnostic method for KVLQT1—a long QT syndrome gene
    Patent number: 6582913
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: June 24, 2003
    Assignees: University of Utah Research Foundation, Genzyme, Inc.
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
    Publication number: 20030054380
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Application
    Filed: May 6, 2002
    Publication date: March 20, 2003
    Applicant: University of Utah Research Foundation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
  • KVLQT1—a long QT syndrome gene
    Patent number: 6451534
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: September 17, 2002
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Mutations in the KCNE1 gene encoding human mink which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
    Patent number: 6432644
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: August 13, 2002
    Assignee: University of Utah Research Foundation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
  • KVLQT1—a long qt syndrome gene
    Patent number: 6420124
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: July 16, 2002
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Mutations in the KCNE1 gene encoding human mink which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
    Patent number: 6323026
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: November 27, 2001
    Assignee: University of Utah Research Foundation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
  • KVLQT1—a long QT syndrome gene
    Patent number: 6277978
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes are also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: August 21, 2001
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
    Patent number: 6274332
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: August 14, 2001
    Assignee: Univ. of Utah Research Foundation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
  • Potassium channel agonists
    Patent number: 6150357
    Abstract: This application discloses a method of treating cardiac ventricular arrhythmias and repolarization abnormalities associated with long QT syndrome and/or congestive heart failure comprising the adminstration of an agonist of the slowly activating cardiac delayed rectifier potassium current (I.sub.Ks).
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: November 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Joseph J. Salata, Jixin Wang, Michael C. Sanguinetti, Nancy K. Jurkiewicz
  • Methods of treating cardiac arrhythmia
    Patent number: 5597818
    Abstract: Benzodiazepine analogs have been found to be useful in treating cardiac abnormalities.
    Type: Grant
    Filed: March 20, 1995
    Date of Patent: January 28, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Michael C. Sanguinetti, Joseph J. Salata, Joseph J. Lynch, Jr.
  • Methods of treating cardiac arrhythmia
    Patent number: 5428031
    Abstract: Benzodiazepine analogs have been found to be useful in treating cardiac abnormalities.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: June 27, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Michael C. Sanguinetti, Joseph J. Lynch, Jr., Joseph J. Salata